Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
Florence Coussy, Marion Lavigne, Leanne de Koning, Rania El Botty, Fariba Némati, Adnan Naguez, Guillaume Bataillon, Bérengère Ouine, Ahmed Dahmani, Élodie Montaudon, Pierre Painsec, Sophie Château‐Joubert, Laetitia Fuhrmann, Thibaut Larcher, Sophie Vacher, Walid Chemlali, Adrien Briaux, Samia Melaabi, Anne Vincent‐Salomon, Jean Marc Guinebretière, Ivan Bièche, Elisabetta Marangoni
Abstract
et la diffusion de documents scientifiques de niveau recherche, publis ou non, manant des tablissements d'enseignement et de recherche franais ou trangers, des laboratoires publics ou privs.
Topics & Concepts
EnzalutamideAndrogen receptorTriple-negative breast cancerProstate cancerPI3K/AKT/mTOR pathwayCancer researchMedicineBreast cancerOncologyCancerInternal medicineChemistryBiochemistrySignal transductionAdvanced Breast Cancer TherapiesProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies